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 Podocyte ACE2 protects against 
diabetic nephropathy 
 Raymond C.  Harris 1 
 As new components of the renin – angiotensin system (RAS) are 
elucidated, our understanding of the complexities of their interactions 
also advances. Previous studies have determined that podocytes 
possess a local RAS that can generate angiotensin II. Podocytes have 
also been shown to express angiotensin-converting enzyme 2 (ACE2), 
which can decrease angiotensin II levels by generation of angiotensin-
(1 – 7). Nadarajah  et al. now show that increased podocyte ACE2 activity 
can attenuate the development of diabetic nephropathy. 
 Kidney International (2012)  82, 255 – 256.  doi: 10.1038/ki.2012.127 
 Th e renin – angiotensin system (RAS) is 
phylogenetically ancient, and its impor-
tance in the maintenance of physiologic 
homeostasis is reflected by the tens of 
thousands of publications on the subject. 
However, although renin was fi rst des-
cribed in 1898 and angiotensin in 1936, 
investigators continue to discover new 
facets of the RAS. Th e role of the mono-
carboxyl peptidase angiotensin-convert-
ing enzyme 2 (ACE2) in physiology and 
pathophysiology has attracted increasing 
interest. While ACE converts the decapep-
tide angiotensin I to angiotensin II by 
removing the two distal amino acids, 
ACE2 can act on both angiotensin I and 
angiotensin II. In both situations, it 
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removes the most distal amino acid, lead-
ing to production of angiotensin-(1 – 9) 
(Ang-1 – 9) and angiotensin-(1 – 7) (Ang-
1 – 7), respectively. Ang-1 – 9 is then further 
metabolized by ACE to give Ang-1 – 7. 
Although ACE2 shares approxi mately 
40 % homology with the classic ACE, it 
is the product of a separate gene and 
is under separate regulatory control. 1 
Importantly, ACE inhibitors in clinical 
practice do not inhibit ACE2. 
 In general, studies have indicated that 
ACE2-mediated responses counteract 
those generated by ACE-mediated pro-
duction of angiotensin II and promote 
vasodilation, natriuresis, and cytoprotec-
tion. Mice with global ACE2 deletion have 
increased responsiveness to RAS activa-
tion. 2 Maternal ACE2 defi ciency leads to 
fetal growth restriction, possibly second-
ary to increased placental concentrations 
of angiotensin II. 3 ACE2 has also been 
implicated in regulation of oxidative stress 
in the paraventricular nucleus and rostral 
ventrolateral medulla, which may modu-
late sympathetic tone and blood pressure. 
Although in a manner that is not related 
to its role in regulation of the RAS, ACE2 
serves as the receptor in the lung for the 
severe acute respiratory syndrome coro-
navirus, and ACE2-defi cient mice do not 
develop lung injury upon exposure to the 
virus. 4 
 Th ere remains uncertainty about exactly 
how ACE2 ’ s eff ects are mediated. On the 
one hand, by conversion of both angio-
tensin I and angiotensin II to Ang-1 – 7, 
ACE2 modulates the amount of angio tensin 
II that is available to activate angio tensin II 
type 1 receptors, while on the other 
hand, Ang-1 – 7 is itself a ligand for the Mas 
receptor, activation of which has been 
reported to mediate vaso dilation, natriure-
sis, and reductions in blood pressure. 5 
Depending on the tissue and the patho-
physiologic condition, one or the other of 
these mechanisms may predominate, or 
they may work in concert. In any event, 
abnormalities in ACE2 expression and / or 
activity have now been implicated in a 
range of disorders, including hypertension, 
cardiovascular disease, and diabetic nephro-
pathy. 
 Studies in patients with diabetic 
nephropathy have shown increases in the 
ACE / ACE2 ratio in both glomerulus and 
tubulo interstitium, due largely to decreased 
ACE2 expression. 6 Previous studies in dia-
betic mice found that either global ACE2 
deletion or pharmacologic ACE2 inhibi-
tion exacerbated development of diabetic 
nephropathy. 7,8 Although these studies did 
not report any alterations of blood pressure 
with inhibition of ACE2 activity or expres-
sion, amelioration of diabetic nephropathy 
with systemic administration of recom-
binant ACE2 or increases in systemic 
ACE2 by adenoviral expression was associ-
ated with decreases in blood pressure, 9,10 
making it difficult to discern whether 
beneficial effects of ACE2 were a local 
response in the kidney or were secondary 
to systemic eff ects on blood pressure. 
 In the glomerulus, the podocyte 
expresses many components of the RAS, 
including the (pro)renin receptor, angio-
tensinogen, ACE, and the angiotensin II 
type 1 receptor. 11 Podocytes also express 
ACE2, 12 although glomerular expression 
of the Mas receptor remains uncertain. In 
previous studies, Mas was detected not in 
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glomeruli but only in the proximal tubule 
and juxtamedullary region, 13,14 although 
global deletion of Mas induces hyperfi ltra-
tion and albuminuria ( Figure 1 ). 
 In order to test directly the role of 
local glomerular ACE2 in diabetic nephro-
pathy, Nadarajah  et al. 15 (this issue) have 
developed a mouse model with selective 
podocyte overexpression of ACE2 by 
coupling the human ACE2 transcript to 
the nephrin promoter. Th e mice were on 
the FVB / n background, which is relatively 
sensitive to development of diabetic 
nephro pathy, and when these mice were 
rendered diabetic by streptozotocin 
administration, the selective ACE2 over-
expression in the podocytes delayed the 
onset of severe functional and structural 
glomerular changes. Specifi cally, there 
was a delay in the onset of significant 
albuminuria, a delay in development of 
signifi cant mesangial expansion, a partial 
preservation of podocyte number, a delay 
in increases in glomerular expression of 
transforming growth factor-  (TGF-  ), 
and preservation of expression of the 
podocyte markers nephrin and synap-
topodin. Notably, these changes were not 
accompanied by any detectable diff erences 
in blood pressure between wild-type and 
transgenic diabetic mice, suggesting that 
the observed benefi cial eff ects were due to 
direct, local eff ects at the glomerulus. 
 As with any well-performed study, these 
results raise a number of interesting ques-
tions. First and foremost of course are the 
exact mechanism and sites of action. Is 
this eff ect only due to relative inhibition 
of local podocyte angiotensin II produc-
tion and angiotensin II type 1 receptor 
activation? If so, one might expect that 
with administration of an ACE inhibitor 
or an angiotensin receptor blocker, there 
might not be any additional benefi t seen 
in the transgenic mice. Conversely, if 
increased Ang-1 – 7 underlies the observed 
benefi cial eff ects of podocyte overexpres-
sion of ACE2, what is its site of action, as 
there is no evidence to date that podocytes 
express Mas? In this regard, this group 
has previously described that cultured 
mesangial cells do express Mas and res-
pond to Ang-1 – 7. 16 Other questions 
include the site of production and role of 
altered TGF-  in the ACE2 eff ects, espe-
cially since the aforementioned study in 
mesangial cells indicated that Ang-1 – 7 
actually stimulated TGF-  production 
rather than inhibiting it. In a previous 
study by this group in a 5 / 6 nephrectomy 
mouse model, ACE2 inhibition worsened 
proteinuria, while administration of Ang-
1-7 had no eff ect and actually increased 
mesangial expansion. 17 
 In summary, the study by Nadarajah 
 et al. 15 clearly shows that podocyte 
ACE2 overexpression can delay and 
ameliorate the development of glomeru-
lopathy in a type 1 model of diabetes, 
indicating that in addition to systemic 
eff ects, ACE2 can slow diabetic nephro-
pathy by direct eff ects on the glomerulus. 
Th erefore, modulation of the ACE2 path-
way represents a potentially exciting 
target for therapeutic intervention. Fur-
ther studies to unravel the mechanisms 
underlying this protection will be 
required in order to determine whether 
increasing ACE2 activity or activating 
Ang-1-7-mediated signaling pathways 
will be the most successful mode of inter-
vention ( Figure 1 ). 
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 Figure 1  |  The podocyte renin – angiotensin system and the mechanisms by which increased 
ACE2 expression can decrease local angiotensin II production. ACE2, angiotensin-converting 
enzyme 2; Ang-1-7, angiotensin-(1-7); Ang-1-9, angiotensin-(1-9); AT 1 , angiotensin II type 1 
receptor; GBM, glomerular basement membrane. 
